A Phase 1/2 Multicenter Dose-Escalation Study to Determine the Safety Efficacy and Pharmacokinetics of TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
Investigation of an Investigational Treatment for Condition X
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Soft Tissue Sarcoma
Age:
18 years - 100 years
Gender: All
Who can participate: Eligible participants are adults aged 18 to 65 with a confirmed diagnosis of Condition X. Key inclusion criteria include stable medical condition and no history of adverse reactions to similar treatments.
Study details: Participants will be randomly assigned to receive either the investigational treatment or a placebo. The study will involve regular monitoring of health parameters and assessment of treatment effects.
Updated on
19 Feb 2024.
Study ID: 1011003282 (0903-12)
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
